Drug Trial Radar · NCT07206225
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
294
Planned (sponsor's estimate)
Start
Nov 6, 2025
Primary completion
Jan 29, 2030
Study completion Jan 28, 2033
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Oct 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn how a new medicine called PF-08052667 works when used by itself or together with another medicine called Bacillus Calmette Guerin (BCG), and/or a medicine called sasanlimab. This study is for adults who have a type of bladder cancer that hasn't spread into the muscle layer of the bladder but is more likely to come back or grow. It includes people whose cancer has come back or hasn't gone away after receiving standard treatments like BCG. It may also include people who, based on their doctor's opinion, cannot receive standard treatments or those treatments are not available to them. The study has three parts: * Part 1 (monotherapy dose escalation) will test PF-08052667 as a single-agent at increasing dose levels in participants with certain bladder cancer whose disease has worsened on or after standard treatments. * Part 2 (combination dose escalation) will test PF-08052667 in combination with BCG and/or sasanlimab (fixed dose) in participants with certain bladder cancer whose disease has worsened on or after standard treatments. * Part 3 (dose optimization and expansion) will further test PF-08052667 as a single agent or in combination with BCG and/or sasanlimab, at the dose(s) based on findings from Part 1 and Part 2 in participants with certain bladder cancer including those who has never received standard treatments. All participants will receive the study drug PF-08052667. Only participants in Part 2 and Part 3 of the study will also receive BCG and/or sasanlimab. PF-08052667 will be given as an intravesical infusion, which means it will be injected directly into the bladder. Sasanlimab will be given as a subcutaneous injection, which means it will be injected under the skin. For all parts, treatment with study medicines will continue until either a participant has decided to stop taking part in the study or is asked to leave the study for various reasons or up to about 2 years, whichever occurs first. Duration of trial participation for each participant will vary as long-term follow-up will continue after treatment discontinuation until loss to-follow-up or death, or until the study is stopped by the sponsor.
Conditions
- Non-muscle Invasive Bladder Cancer
Interventions
PF-08052667Drug
PF-08052667 will be administered intravesical (IVe) instillation following a PF-02921367 (DDM) bladder pre-wash
SasanlimabDrug
Sasanlimab will be administered as subcutaneous (SC) injection
BCGDrug
BCG will be administered intravesical (IVe) instillation
PF-02921367Drug
PF-02921367 (DDM) is a 10-min pre- wash and will be administered intravesical (IVe) instillation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with dose limiting toxicities (DLTs) in dose escalation in Part 1 and Part 2 participants onlyTime frame: Day of first dose (Day 1) Up to 21 days
- Number of participants with adverse events (AEs) in Part 1 and Part 2 participants onlyTime frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
- Number of participants with laboratory abnormalities in Part 1 and Part 2 participants onlyTime frame: From the first day through 30-37 days after the last study treatment, up to approximately 2 years
- Recurrence-free survival (RFS) in Part 3 participants onlyTime frame: Through end of study and up to approximately 2 years
- Event-free survival (EFS) in Part 3 participants onlyTime frame: Through end of study and up to approximately 2 years
Locations
69 sites in 6 countries. Site status is shown where the registry gives one.
The Kirklin Clinic of UAB Hospital
Birmingham, Alabama · Recruiting
UAB Infusion Therapy Extended Care Clinic (ECC)
Birmingham, Alabama · Recruiting
The University of Alabama at Birmingham Investigation Drug Services Pharmacy
Birmingham, Alabama · Recruiting
University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
Moffitt Cancer Center at SouthShore
Ruskin, Florida · Recruiting
Moffitt Cancer Center - International Plaza
Tampa, Florida · Recruiting
Moffitt Cancer Center - McKinley Campus
Tampa, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Moffitt McKinley Hospital
Tampa, Florida · Recruiting
Moffitt Cancer Center at Wesley Chapel
Wesley Chapel, Florida · Recruiting
Emory University Hospital Midtown
Atlanta, Georgia · Recruiting
Emory Children's Center
Atlanta, Georgia · Recruiting
Emory University Hospital
Atlanta, Georgia · Recruiting
Emory University
Atlanta, Georgia · Recruiting
Northwestern Memorial Hospital
Chicago, Illinois · Not yet recruiting
Northwestern University - Feinberg School of Medicine
Chicago, Illinois · Not yet recruiting
University of Iowa Health Care
Iowa City, Iowa · Recruiting
The University of Kansas - Clinical Research Center
Fairway, Kansas · Recruiting
The University of Kansas Hospital Cambridge North Tower A
Kansas City, Kansas · Recruiting
The University of Kansas Hospital
Kansas City, Kansas · Recruiting
The University of Kansas Medical Center Medical Office Building
Kansas City, Kansas · Recruiting
The University of Kansas Hospital - Indian Creek Campus
Overland Park, Kansas · Recruiting
The University of Kansas Cancer Center - Westwood
Westwood, Kansas · Recruiting
MSK Basking Ridge
Basking Ridge, New Jersey · Recruiting
MSK Monmouth
Middletown, New Jersey · Recruiting
MSK Bergen
Montvale, New Jersey · Recruiting
MSK Commack
Commack, New York · Recruiting
MSK Westchester
Harrison, New York · Recruiting
Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center 53rd street
New York, New York · Recruiting
Icahn School of Medicine at Mount Sinai
New York, New York · Recruiting
64th Street Outpatient and Innovation Center
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center - Main Campus
New York, New York · Recruiting
Sidney Kimmel Center for Prostate and Urological Cancers - Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Upstate Specialty Services at Harrison Center
Syracuse, New York · Recruiting
SUNY Upstate Medical University
Syracuse, New York · Recruiting
SUNY Upstate Medical University-Community Campus
Syracuse, New York · Recruiting
MSK Nassau
Uniondale, New York · Recruiting
Biorepository and Precision Pathology Center (BRPC)
Durham, North Carolina · Recruiting
Duke Cancer Institute
Durham, North Carolina · Recruiting
Showing 40 of 69 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.